相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas
Jakub Svoboda et al.
HAEMATOLOGICA (2021)
Mutational landscape of gray zone lymphoma
Clementine Sarkozy et al.
BLOOD (2021)
Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial
G. A. Amos Burke et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies
Theodoros P. Vassilakopoulos et al.
ANNALS OF HEMATOLOGY (2021)
Characterization of DLBCL with a PMBL gene expression signature
Gerben Duns et al.
BLOOD (2021)
Real-world data on treatment and outcomes of patients with primary mediastinal large B-cell lymphoma: a Swedish lymphoma register study
Tove Wasterlid et al.
BLOOD CANCER JOURNAL (2021)
Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma
Agata Malenda et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report
Stuart E. Lacy et al.
BLOOD (2020)
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
George W. Wright et al.
CANCER CELL (2020)
Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up
Hui Zhou et al.
BLOOD CANCER JOURNAL (2020)
Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach
Anna R. Hayden et al.
BLOOD (2020)
Gene expression profiling of gray zone lymphoma
Clementine Sarkozy et al.
BLOOD ADVANCES (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
Gene Expression Profiling of Mediastinal Gray Zone Lymphoma and Its Relationship to Primary Mediastinal B-cell Lymphoma and Classical Hodgkin Lymphoma
Stefania Pittaluga et al.
BLOOD CANCER DISCOVERY (2020)
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
Nancy L. Bartlett et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma
Anja Mottok et al.
BLOOD (2019)
Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma
Esther Hian Li Chan et al.
CANCER MEDICINE (2019)
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study
Pier Luigi Zinzani et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade
Bjoern Chapuy et al.
BLOOD (2019)
Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma
Seok Jin Kim et al.
BMC CANCER (2019)
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome
Gerben Duns et al.
BLOOD (2019)
Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
Daisuke Ennishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma
Marcus Messmer et al.
LEUKEMIA & LYMPHOMA (2019)
Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant
Santosha Vardhana et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma
Luca Ceriani et al.
BLOOD (2018)
Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation
Elena Vigano et al.
BLOOD (2018)
Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation
Irit Avivi et al.
BONE MARROW TRANSPLANTATION (2018)
Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma
Yosuke Tanaka et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making
Christopher Melani et al.
HAEMATOLOGICA (2018)
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy et al.
NATURE MEDICINE (2018)
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
R. Schmitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making
Christopher Melani et al.
HAEMATOLOGICA (2018)
Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens
Anja Mottok et al.
BLOOD (2018)
Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma
Rachel J. David et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL
Chelsea C. Pinnix et al.
BLOOD ADVANCES (2018)
R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis
Nirav N. Shah et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association
Clementine Sarkozy et al.
HAEMATOLOGICA (2017)
Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association
Clementine Sarkozy et al.
HAEMATOLOGICA (2017)
Secondary Breast Cancer Risk by Radiation Volume in Women With Hodgkin Lymphoma
Jessica L. Conway et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma
Luca Ceriani et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Determination of Molecular Subtypes of Diffuse Large B-Celt Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier A CALYM Study
Victor Bobee et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R
Lisa Giulino-Roth et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma
Pier Luigi Zinzani et al.
BLOOD (2017)
Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma
K. Lisenko et al.
BMC CANCER (2017)
Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial
Pier Luigi Zinzani et al.
BLOOD (2017)
Performance of a Commercially Available MAL Antibody in the Diagnosis of Primary Mediastinal Large B-Cell Lymphoma
Michael Gentry et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy
T. P. Vassilakopoulos et al.
LEUKEMIA (2016)
Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas
Lauren C. Chong et al.
BLOOD (2016)
Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma
Larry Mansouri et al.
BLOOD (2016)
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial
Mary Gleeson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy
Neta Goldschmidt et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Improved Survival With Radiation Therapy in Stage I-II Primary Mediastinal B Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis
Matthew W. Jackson et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study
Nickhill Bhakta et al.
LANCET ONCOLOGY (2016)
Response to 'PET after response to R-CHOP in primary mediastinal large B-cell lymphoma'
T. P. Vassilakopoulos et al.
LEUKEMIA (2016)
Role of radiation therapy in primary mediastinal large B-cell lymphoma in rituximab era: A US population-based analysis
Smith Giri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling
Ji Yuan et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Genomic alterations underlying immune privilege in malignant lymphomas
Anja Mottok et al.
CURRENT OPINION IN HEMATOLOGY (2015)
Alterations of the CD58 gene in classical Hodgkin lymphoma
Markus Schneider et al.
GENES CHROMOSOMES & CANCER (2015)
Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment by 18Fluorodeoxyglucose Positron Emission Tomography
Chelsea C. Pinnix et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies
David W. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Structural genomic alterations in primary mediastinal large B-cell lymphoma
David D. W. Twa et al.
LEUKEMIA & LYMPHOMA (2015)
Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma
Michael Schaapveld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma
T. Aoki et al.
BLOOD CANCER JOURNAL (2015)
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients
Pier Luigi Zinzani et al.
HEMATOLOGICAL ONCOLOGY (2015)
Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated With PDCD1LG2 Copy Gain
Min Shi et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)
The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma
Abraham Avigdor et al.
ANNALS OF HEMATOLOGY (2014)
Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma
David D. W. Twa et al.
BLOOD (2014)
Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan
Tomohiro Aoki et al.
HAEMATOLOGICA (2014)
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Sally F. Barrington et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
[18F] Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study
Maurizio Martelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease
Jacob D. Soumerai et al.
LEUKEMIA & LYMPHOMA (2014)
Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma
Jay Gunawardana et al.
NATURE GENETICS (2014)
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Benjamin J. Chen et al.
CLINICAL CANCER RESEARCH (2013)
Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy
Li-Ming Xu et al.
LEUKEMIA & LYMPHOMA (2013)
Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma
Kieron Dunleavy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Utility of CD200 immunostaining in the diagnosis of primary mediastinal large B cell lymphoma: comparison with MAL, CD23, and other markers
David M. Dorfman et al.
MODERN PATHOLOGY (2012)
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care
Theodoros P. Vassilakopoulos et al.
ONCOLOGIST (2012)
Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study
M. Rieger et al.
ANNALS OF ONCOLOGY (2011)
Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma
Madhavi Challa-Malladi et al.
CANCER CELL (2011)
Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations
Franziska C. Eberle et al.
MODERN PATHOLOGY (2011)
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
Christian Steidl et al.
NATURE (2011)
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
Michael R. Green et al.
BLOOD (2010)
Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients
Hee Kyung Ahn et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Sequential Dose-Dense RCHOP Followed by ICE Consolidation (MSKCC protocol 01-142) without Radiotherapy for Patients with Primary Mediastinal Large B Cell Lymphoma
Craig Moskowitz et al.
BLOOD (2010)
Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma
Olga Ritz et al.
BLOOD (2009)
TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma
Roland Schmitz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Rituximab Combined With MACOP-B or VACOP-B and Radiation Therapy in Primary Mediastinal Large B-Cell Lymphoma: A Retrospective Study
Pier Luigi Zinzani et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Heterogeneous CD52 expression among hematologic neoplasms: Implications for the use of alemtuzumab (CAMPATH-1H)
Scott J. Rodig et al.
CLINICAL CANCER RESEARCH (2006)
Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival
Robin A. Roberts et al.
BLOOD (2006)
AID expression identifies interfollicular large B cells as putative precursors of mature B-cell malignancies
G Moldenhauer et al.
BLOOD (2006)
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
A Rosenwald et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma
KJ Savage et al.
BLOOD (2003)
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy
WH Wilson et al.
BLOOD (2002)
分享论文
